Compare Meta Platforms Inc (META) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Viatris Inc — how do they compare? Meta Platforms Inc trades at $718.67 (market cap $1.84T), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Meta Platforms Inc is far larger — about 91.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Viatris Inc for 57 Days on average.
| META | VTRS | |
|---|---|---|
Market Cap | $1.84T | $20.03B |
Volume | 15,887,049 | 14,109,977 |
Sector | Media | Health |
52-Week High | $777.59 | $18.27 |
52-Week Low | $525.72 | $9.74 |
Typical Hold Time | 127 Days | 57 Days |
Enterprise Value | $1.86T | $32.15B |
Dividend Yield | 0.29% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $718.67, down 0.37% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $201B in 2025 and maintains robust profitability with 29.84% net margins. Recent AI developments, including the Muse Spark launch, and a $21B deal with CoreWeave highlight strategic positioning. Analyst consensus is strongly bullish with an 80% buy rating and $781 price target, though legal challenges and high capital expenditures present headwinds.
META's outlook remains positive driven by AI innovation and solid fundamentals, but investors face risks from regulatory lawsuits and volatile tech sentiment. The stock offers upside to consensus targets if execution continues, yet high valuation multiples and market rotation pressures warrant caution. Balancing growth prospects with legal and competitive risks is key for medium-term performance.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
